Literature DB >> 11309352

Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway.

M Li1, X Wu, X C Xu.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown cancer preventive activity in patients who took them frequently. These drugs can induce tumor cells to undergo apoptosis in vitro. NS398, a cyclooxygenase-2 (COX-2)-selective inhibitor, has been reported to cause apoptosis in cancer cell lines. Therefore, we examined its effect on 15 human colon cancer cell lines and investigated its mechanism of action. NS398 decreased cell viability in all of the cell lines. Tumor cells that expressed COX-2 were shown to be more sensitive to NS398 treatment. In three selected colon cancer cell lines, NS398-induced apoptosis was mediated by the release of cytochrome c from mitochondria and, consequently, by the activation of caspase-9 and caspase-3 and by the cleavage of poly(ADP-ribose) polymerase. In contrast, caspase-8 was not involved in NS398-induced apoptosis, which suggested that the cytochrome c pathway may play an important role in NS398-induced apoptosis in colon cancer cell lines. Therefore, the combination of NS398 with apoptosis-inducing drugs through cytochrome c-independent pathways may be warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309352

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage.

Authors:  Katarina Wikström; Maria Juhas; Anita Sjölander
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 2.  Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer.

Authors:  Milind Rao; Wenxuan Yang; Alexander M Seifalian; Marc C Winslet
Journal:  Int J Colorectal Dis       Date:  2003-06-03       Impact factor: 2.571

Review 3.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

4.  Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus.

Authors:  Hiroshi Yasuda; Masaya Yamada; Yutaka Endo; Kazuaki Inoue; Makoto Yoshiba
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

5.  Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.

Authors:  Hiroki Takahashi; Aihua Li; David W Dawson; Oscar Joe Hines; Howard A Reber; Guido Eibl
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

6.  Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2.

Authors:  Hiroshi Nishihara; Shinae Kizaka-Kondoh; Paul A Insel; Lars Eckmann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-01       Impact factor: 11.205

7.  Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.

Authors:  Bin Su; Michael V Darby; Robert W Brueggemeier
Journal:  J Comb Chem       Date:  2008-04-02

8.  Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.

Authors:  Su-Hyeong Kim; Sang-Hyun Song; Sang-Gyun Kim; Kyung-Soo Chun; So-Young Lim; Hye-Kyung Na; Jae Weon Kim; Young-Joon Surh; Yung-Jue Bang; Yong-Sang Song
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-10       Impact factor: 4.553

9.  Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells.

Authors:  Quanxin Wang; Yoshiyuki Takei; Osamu Kobayashi; Taro Osada; Sumio Watanabe
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

10.  Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.

Authors:  O Galamb; S Spisák; F Sipos; K Tóth; N Solymosi; B Wichmann; T Krenács; G Valcz; Z Tulassay; B Molnár
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.